IDH2 and astrocytoma (excluding glioblastoma): Therefore, these findings not only corroborate the detrimental effect of CDKN2A homozygous deletion on patient survival of IDH-mutant astrocytoma, but also suggest its negative impact on the tumor-suppressive activity of IDH mutation, either directly or indirectly.